Latest News on WAT

Financial News Based On Company


Advertisement
Advertisement

STERIS plc (Ireland) (STE) Stock forecasts

https://sg.finance.yahoo.com/research/reports/ARGUS_4272_QuantitativeReport_1794960000000
This article provides a brief overview of STERIS plc (STE), an Ireland-domiciled medical technology company specializing in sterilization services and infection prevention. It highlights an Argus report from November 18, 2026, which includes a current price of $254.76 for STE and offers access to a full report with a price target. The article also lists other related analyst reports for various companies.

Life sciences tools & services stocks Q3 recap: Benchmarking Illumina

https://www.tradingview.com/news/stockstory:b8fb8dda9094b:0-life-sciences-tools-services-stocks-q3-recap-benchmarking-illumina/
The life sciences tools and services sector experienced a solid Q3, with revenues beating analyst estimates and positive next-quarter guidance, despite a collective share price decline of 3.3% since recent earnings. The article benchmarks Illumina (ILMN), which reported strong Q3 revenues exceeding expectations but saw its stock drop 27.9%. In contrast, Azenta (AZTA) had the best Q3 performance among peers, with its stock rising 20.3% after impressive results.

Waters Corp. stock outperforms competitors on strong trading day

https://www.marketwatch.com/data-news/waters-corp-stock-outperforms-competitors-on-strong-trading-day-edae71b2-870d8972ad1e?mod=mw_quote_news
Shares of Waters Corp. (WAT) rose 3.63% to $466.10 on Wednesday, outperforming the broader market which saw the S&P 500 Index fall 0.23% and the Dow Jones Industrial Average drop 1.11%. This increase ended a six-day losing streak for the company's stock.

Investors Can Find Comfort In Waters' (NYSE:WAT) Earnings Quality

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-wat/waters/news/investors-can-find-comfort-in-waters-nysewat-earnings-qualit
Waters Corporation's recent weak earnings report did not significantly impact its stock movement, but underlying weaknesses raise investor concerns. The company issued 65% more new shares over the last year, leading to dilution that exacerbated an 85% profit decline and an 89% EPS fall over the same period. Additionally, unusual items reduced profit by US$633 million, making statutory profit appear worse than underlying earnings.

Waters Corporation to Present at the 9th Annual Evercore Healthcare Conference

http://www.streetinsider.com/PRNewswire/Waters+Corporation+to+Present+at+the+9th+Annual+Evercore+Healthcare+Conference/27360827.html
Waters Corporation announced that its President and CEO, Udit Batra, Ph.D., will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference on December 1, 2026, at 9:10 AM Eastern Time. A live webcast and replay of the event will be available on the company's Investor Relations website. Waters Corporation is a global leader in life sciences and diagnostics, focusing on analytical technologies, informatics, and service.
Advertisement

Life Sciences and Laboratory Equipment Market Size, Share & Forecast 2036

https://www.factmr.com/report/life-sciences-and-laboratory-equipment-market
The Life Sciences and Laboratory Equipment Market is projected to reach USD 214.2 billion by 2036, growing at a CAGR of 6.9% from USD 109.9 billion in 2026. This growth is driven by expanding drug discovery, manufacturing investments by pharmaceutical companies, and increasing demand for analytical equipment and automated laboratory solutions. Key players are consolidating and integrating workflows to meet complex testing requirements and secure recurring revenue.

Waters Corporation to Present at the 9th Annual Evercore Healthcare Conference

https://sg.finance.yahoo.com/news/waters-corporation-present-9th-annual-140000248.html
Waters Corporation announced that its President and CEO, Udit Batra, Ph.D., will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference on December 1, 2026, at 9:10 AM Eastern Time. A live webcast of the event will be available on the company's Investor Relations website, with a replay accessible for 90 days. Waters Corporation is a global leader in life sciences and diagnostics, focusing on analytical technologies, informatics, and services to advance medicine, ensure safety, and improve patient outcomes.

Here’s How Much You Would Have Made Owning Waters Stock In The Last 20 Years

https://www.benzinga.com/news/26/11/63320369/here-s-how-much-you-would-have-made-owning-waters-stock-last-20-years
Waters (NYSE: WAT) has outperformed the market over the last two decades, generating an average annual return of 11.61%. An initial investment of $1000 in WAT stock 20 years ago would now be worth $8,893.68, demonstrating the significant impact of compounded returns. The company currently holds a market capitalization of $90.45 billion.

Waters Corp. stock underperforms Monday when compared to competitors

https://www.marketwatch.com/data-news/waters-corp-stock-underperforms-monday-when-compared-to-competitors-0a165cb5-70c37bc43583
Waters Corp. shares fell 1.48% on Monday, closing at $453.42, marking its fifth consecutive day of losses. This decline occurred during a broader market downturn, with the S&P 500 Index dropping 1.92% and the Dow Jones Industrial Average falling 1.41%.

Thermo Fisher Scientific (TMO) Dividend And Bond Moves Leave Valuation Questions Open

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/thermo-fisher-scientific-tmo-dividend-and-bond-moves-leave-v
Thermo Fisher Scientific (TMO) has announced a quarterly cash dividend of $0.47 per share and completed new Swiss franc bond offerings, providing investors with insight into its shareholder returns and funding strategy. While the stock has seen significant gains recently, analyst consensus views it as fairly valued at $750.92, whereas a DCF model suggests it might be overvalued at its current price of $699.44. These mixed signals, combined with an upcoming executive retirement, create valuation questions for investors.
Advertisement

Delco life sciences company acquired in $108M deal

https://www.bizjournals.com/philadelphia/news/2026/11/12/mobilion-systems-chadds-ford-waters-sale.html
Mobilion Systems, a life sciences company based in Delaware County, has been acquired by Waters Corp. in a $108 million deal. Prior to this acquisition, Mobilion Systems had raised approximately $110 million from private investors since its inception.

MediWound's Penny EPS Beat Is Overshadowed By A 53% Revenue Miss And A Retreat From Its 2026 Revenue Outlook

https://finviz.com/news/421924/mediwounds-penny-eps-beat-is-overshadowed-by-a-53-revenue-miss-and-a-retreat-from-its-2026-revenue-outlook
MediWound technically beat EPS estimates but missed revenue consensus by 53.2% and retracted its 2026 revenue outlook due to unpredictable U.S. government funding. While the company saw improvements in gross margin, NexoBrid demand, and government contracts, its near-term financial stability is compromised, and the balance sheet required fresh equity. Investors are now focused on the mid-2027 VALUE clinical trial readout and capacity expansion rather than immediate revenue figures.

Greater Philadelphia Life Sciences News: INOVIO's $75M Offering, Waters' MOBILion Acquisition & More

https://biobuzz.io/news/greater-philadelphia-life-sciences-news-inovio-s-75m-offering-waters-mobilion-acquisition/
The Greater Philadelphia life sciences ecosystem is experiencing significant activity, with companies raising capital, acquiring capabilities, and building talent pipelines. Notable events include INOVIO Pharmaceuticals pricing a $75 million public offering, Waters Corporation acquiring MOBILion Systems, and Charles River Laboratories expanding its preclinical drug development platform through an acquisition from Frontage. Additionally, the region is seeing leadership appointments and new healthcare training initiatives.

Becton Dickinson stock hits 52-week high at 216.85 USD

https://www.investing.com/news/company-news/becton-dickinson-stock-hits-52week-high-at-21685-usd-93CH-5022277
Becton Dickinson (BDX) stock reached a new 52-week high of $216.85, reflecting robust performance and investor confidence with a 41.96% increase over the past year. InvestingPro analysis suggests the stock is undervalued with a Fair Value of $244.35, indicating potential for further growth. This milestone follows strong fiscal fourth-quarter results and positive analyst upgrades from Jefferies and Wells Fargo.

Bio-Rad Laboratories' (NYSE:BIO) Solid Profits Have Weak Fundamentals

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bio/bio-rad-laboratories/news/bio-rad-laboratories-nysebio-solid-profits-have-weak-fundame
Bio-Rad Laboratories' stock has not significantly moved despite strong earnings, primarily due to concerns about the sustainability of its profits. An unusual US$1.0 billion gain from non-recurring items substantially boosted reported profit, leading analysts to believe that statutory earnings may not accurately reflect the company's underlying profitability. Investors are advised to look beyond the reported profits and consider other factors like margins, growth forecasts, and potential risks.
Advertisement

Waters Corporation Reports $127M Net Loss for First Nine Months of 2026 Amid Acquisition-Driven Growth

https://kalkinemedia.com/us/news/announcements/waters-corporation-reports-127m-net-loss-for-first-nine-months-of-2026-amid-acquisition-driven-growth
Waters Corporation reported a net loss of $127 million for the first nine months of 2026, a significant downturn from a net income of $417 million in the same period of 2025. This loss is primarily attributed to substantial acquisition-related expenses, including $640 million in amortization of purchased intangibles. Despite the loss, the company saw its total net revenues more than double to $4,678 million due to acquisition-driven growth, and its total assets expanded significantly to $24,115 million.

$1.77B in Q3 revenue at Waters (WAT) came with a drop in profit.

https://www.stocktitan.net/sec-filings/WAT/10-q-waters-corp-de-quarterly-earnings-report-f08f4929b176.html
Waters Corporation (WAT) reported a significant increase in Q3 2026 revenue to $1.77 billion, up from $800 million in the prior-year quarter, primarily driven by the acquisition of Becton, Dickinson and Company's Biosciences and Diagnostic Solutions (BDS) business. However, net income for the quarter fell to $81 million from $149 million, and for the first nine months, the company reported a net loss of $127 million compared to a net income of $417 million a year earlier. The decline in profit was largely due to acquisition-related costs, including purchased intangibles amortization, inventory and fixed asset step-up expenses, and restructuring charges from a workforce reduction.

Mettler-Toledo International Inc. (MTD) stock price, news, quote and history

https://au.finance.yahoo.com/quote/MTD/
Mettler-Toledo International Inc. (MTD) stock is currently trading at $1,740.92, down 0.46%. The company, which manufactures and supplies precision instruments across various sectors, has a market capitalization of $34.628 billion. Analysts have an average 1-year target estimate of $1,712.50, with JP Morgan recently maintaining a "Neutral" rating and raising its price target to $1840.

At $210 per share, Becton Dickinson (BDX) CEO Thomas E. Polen Jr. sells 2,993 shares.

https://www.stocktitan.net/sec-filings/BDX/form-4-becton-dickinson-co-insider-trading-activity-aabb031a1de0.html
Becton Dickinson (BDX) Chairman, CEO, and President Thomas E. Polen Jr. exercised stock appreciation rights for 20,239 common shares on November 5, 2026, at an exercise price of $178.94 per share. He subsequently returned 17,246 shares to the issuer and sold 2,993 shares, both at $210 per share. These transactions were conducted under a Rule 10b5-1 plan adopted on March 2, 2026.

Will Raised Guidance Change Waters (WAT) Narrative

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-wat/waters/news/will-raised-guidance-change-waters-wat-narrative
Waters Corporation (WAT) recently reported strong Q3 2026 sales and net income, alongside raised full-year guidance. This optimism is partly driven by the launch of AI Powered Peak Integration in its Empower Software, which aims to automate chromatography workflows and improve efficiency in regulated labs. The article explores how this new technology and the increased guidance fit into Waters' investment narrative, emphasizing potential growth and profitability levers despite integration risks and market challenges.
Advertisement

Bio Rad Laboratories (BIO) Could Be 14% Overvalued After Elliott Interest And Earnings

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bio/bio-rad-laboratories/news/bio-rad-laboratories-bio-could-be-14-overvalued-after-elliot
Bio-Rad Laboratories (BIO) is considered 14% overvalued against its fair value of $335, despite strong third-quarter earnings and interest from Elliott Investment Management. The company's multi-year restructuring program aiming for significant cost savings and improved operating margins has encouraged investors, possibly inflating expectations. While a simple P/E ratio suggests a modest premium, the ongoing debate centers on whether the growth story or the multiple moving closer to peers poses a greater risk.

How $5 Billion Buyback At Thermo Fisher Scientific (TMO) Has Changed Its Investment Story

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/how-5-billion-buyback-at-thermo-fisher-scientific-tmo-has-ch
Thermo Fisher Scientific (TMO) has authorized a new US$5 billion share repurchase program, maintained its dividend at US$0.47 per share, and issued CHF 280 million in Swiss franc bonds. These actions highlight the company's active management of its capital structure and ownership mix, funding its broad life sciences operations. While these capital allocation decisions don't alter the core business drivers, they reinforce Thermo Fisher Scientific's commitment to returning capital to shareholders, alongside strategic operational milestones.

Agilent Technologies (A), What Is Drawing Fresh Attention To The Stock?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-a/agilent-technologies/news/agilent-technologies-a-what-is-drawing-fresh-attention-to-th
Agilent Technologies (A) is gaining attention following the launch of its 5987A mass selective detector with GC Assist and MassHunter 14 software, ahead of its Q4 earnings. The company has seen significant share price returns, including 19.72% over 90 days and 26.68% year-to-date, reflecting investor interest in its product innovation and strategic moves. While the stock is currently assessed as 4% undervalued based on a fair value of $181.05, its P/E ratio of 34.2x suggests a more demanding valuation compared to its fair ratio of 27.2x.

Is Thermo Fisher Scientific (TMO) Reasonable Or Stretched On Cash Flow?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/is-thermo-fisher-scientific-tmo-reasonable-or-stretched-on-c
Thermo Fisher Scientific (TMO) has seen a significant share price increase, prompting an evaluation of whether its cash flow supports its current valuation. A Discounted Cash Flow (DCF) model suggests the stock's intrinsic value is below its current trading price of $694.76, even considering a new $5 billion share repurchase program. The company's future value is debated within the community, with some seeing it as undervalued due to M&A and others as overvalued due to margin and growth constraints.

Instrument revenue fell 43%, yet 10x Genomics (TXG) narrowed its Q3 net loss.

https://www.stocktitan.net/sec-filings/TXG/10-q-10x-genomics-inc-quarterly-earnings-report-af7c6e80f727.html
10x Genomics (TXG) reported a narrowed net loss of $19.4 million in Q3 2026, compared to $27.5 million a year prior, despite a 43% drop in instrument revenue. Overall revenue slightly increased by 1% to $150.7 million, primarily driven by a 5% increase in consumables revenue and an 11% rise in service revenue. For the first nine months of 2026, the company's net loss widened to $50.8 million, and total revenue decreased by 5% due to significantly lower license and royalty revenue compared to the previous year.
Advertisement

Waters acquires MOBILion Systems for bringing advanced ion-mobility separation to mass spectrometry portfolio

https://www.biospectrumindia.com/news/116/28796/waters-acquires-mobilion-systems-for-bringing-advanced-ion-mobility-separation-to-mass-spectrometry-portfolio-.html
Waters Corporation has acquired MOBILion Systems, a pioneer in SLIM high-resolution ion mobility separation technology. This acquisition significantly enhances Waters' presence in the proteomics market by combining SLIM's separation capabilities with Waters' Xevo™ MRT MS, offering superior analysis of complex proteomes. The integration aims to accelerate innovation in the $2 billion LCMS proteomics market and support advanced AI models for biomarker discovery and validation.

Waters Corporation Reports $1.77 Billion In Third Quarter 2026 Revenue And Raises Full-Year Guidance

https://pulse2.com/waters-corporation-reports-1-77-billion-in-third-quarter-2026-revenue-and-raises-full-year-guidance/
Waters Corporation announced third-quarter 2026 revenue of $1.77 billion, surpassing its guidance, driven by organic growth and contributions from acquired businesses. The company reported adjusted earnings per share of $4.10, an increase of 21% year-over-year, and subsequently raised its full-year 2026 financial guidance. This strong performance was attributed to robust consumables growth, new product innovation, and increased customer testing volumes.

$459M in net income comes alongside an operating loss at Bio-Rad (BIO).

https://www.stocktitan.net/sec-filings/BIO/10-q-bio-rad-laboratories-inc-quarterly-earnings-report-c49b56ecb456.html
Bio-Rad Laboratories, Inc. reported a Q3 2026 net income of $458.6 million, a significant turnaround from a $341.9 million net loss a year prior, primarily due to a $583.2 million holding gain on its Sartorius investment. Despite this, the company posted an operating loss of $49.7 million, including a $49.8 million impairment of Celsee-related intangible assets, and incurred $77.6 million in restructuring costs. Net sales for the quarter were $656.4 million, a slight increase of 0.5% year-over-year.

Waters Acquires Chadds Ford’s MOBILion Systems to Expand Into Proteomics With High-Resolution Ion Mobility Technology

https://biobuzz.io/news/waters-acquires-chadds-fords-mobilion-systems-to-expand-into-proteomics-with-high-resolution-ion-mobility-technology/
Waters Corporation has acquired MOBILion Systems, a developer of SLIM high-resolution ion mobility separation technology, to expand its presence in proteomics. This acquisition aims to enhance Waters' mass spectrometry portfolio by integrating SLIM technology to improve the understanding of complex biology and generate high-quality data for AI models. The deal is expected to advance proteomics from research labs into routine clinical testing, including for applications like multi-cancer early detection.

Danaher (DHR) Won FDA Clearances, Is The Discount Too Cautious?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/danaher-dhr-won-fda-clearances-is-the-discount-too-cautious
Danaher (DHR) has gained renewed investor interest following recent FDA clearances for its Cepheid Xpert Hemorrhagic Fever Panel and Beckman Coulter Access MeMed BV assay, enhancing its infectious disease and antimicrobial testing portfolio. Despite positive share price momentum and higher long-term revenue guidance, the stock trades at a discount to analyst targets and intrinsic value estimates. The article explores whether the market is appropriately cautious about execution risks or overly skeptical of Danaher's new diagnostics pipeline and growth prospects.
Advertisement

Becton, Dickinson and Company Q4 Earnings Call Highlights

https://www.tradingview.com/news/marketbeat:2c7123c0d094b:0-becton-dickinson-and-company-q4-earnings-call-highlights/
Becton, Dickinson and Company (BDX) reported higher fiscal fourth-quarter revenue and adjusted earnings, driven by demand for patient monitoring and biologic drug delivery products, offsetting challenges with its Alaris infusion platform. The company provided a fiscal 2027 outlook projecting low-single-digit revenue growth and adjusted EPS of $13.10 to $13.30, with an anticipated return to mid-single-digit growth beyond 2027 as Alaris comparisons fade. BD also highlighted a new agreement with the U.S. government for domestic investment, potentially offering relief from future Section 232 tariffs.

Waters Corporation Acquires MOBILion Systems To Expand Mass Spectrometry And AI-Powered Proteomics Capabilities

https://pulse2.com/waters-corporation-acquires-mobilion-systems-to-expand-mass-spectrometry-and-ai-powered-proteomics-capabilities/
Waters Corporation has acquired MOBILion Systems, a developer of high-resolution ion mobility separation technology, to expand its mass spectrometry portfolio and strengthen its position in proteomics research. This acquisition introduces MOBILion's SLIM technology, which will be integrated with Waters' Xevo MRT mass spectrometry platform, enhancing molecular analysis and supporting AI-driven scientific discovery. The strategic move aims to accelerate Waters' expansion into the liquid chromatography-mass spectrometry proteomics market and enable new applications in clinical diagnostics, such as multi-cancer early detection.

Revvity, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-rvty/revvity/news/revvity-inc-just-beat-analyst-forecasts-and-analysts-have-be
Revvity, Inc. (NYSE:RVTY) recently surpassed analyst expectations for its quarterly report, with revenues reaching US$710m and statutory earnings per share outperforming by 13%. Despite these strong results, analysts have made no significant changes to their 2027 revenue and EPS forecasts, which remain at US$3.03b and US$2.86 respectively, and the consensus price target held steady at US$150. While Revvity's future growth is expected to improve compared to its past performance, it is still projected to lag behind the broader industry's revenue growth.

How Investors May Respond To Agilent (A) New Mass Spectrometer Launch

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-a/agilent-technologies/news/how-investors-may-respond-to-agilent-a-new-mass-spectrometer
Agilent Technologies recently launched its 5987A single quadrupole mass selective detector with GC Assist and MassHunter 14, which integrates with their 8890B and 8860B gas chromatographs to improve lab efficiency, automation, and energy consumption. This launch aligns with Agilent's strategy to deliver high-end lab hardware, software, and services for steadier, higher-margin cash flows, especially by focusing on software and data-heavy workflows. While the new GC/MS system supports the investment narrative, risks include pressure on research budgets and integration complexity for advanced instruments and software.

BD Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results

https://investors.bd.com/news-events/press-releases/detail/984/bd-reports-fourth-quarter-and-full-year-fiscal-2026-financial-results
BD (Becton, Dickinson and Company) announced strong financial results for its fiscal 2026 fourth quarter and full year, ending September 30, 2026, with Q4 revenue increasing 5.4% to $5.3 billion and full-year revenue up 4.9% to $19.5 billion. The company reported significant growth in GAAP and adjusted diluted EPS and free cash flow, while also providing positive fiscal 2027 guidance. Key business highlights included a $19 billion partnership with the U.S. Government for domestic manufacturing, the deployment of its BD Vmax 160 Pharmacy Automation Robot, and advancements in peripheral vascular and advanced tissue regeneration innovations.
Advertisement

[Becton, Dickinson and Q4 2026 Earnings Call] BD Posts 27% EPS Jump to $4.15 as Medtech Pure-Play Debuts; FY2027 Guide of $13.10-$13.30 Disappoints as Alaris Headwind Looms

https://finance.biggo.com/news/US_BDX_2026-11-05
Becton, Dickinson and Company (BD) reported strong fourth-quarter 2026 results with a 27.3% surge in adjusted diluted EPS to $4.15 and 5.6% FX-neutral revenue growth, completing its first year as a medtech pure-play. However, the company's fiscal 2027 guidance for low single-digit revenue growth and $13.10-$13.30 adjusted EPS disappointed analysts, primarily due to an Alaris capital comparison headwind. Management defended the outlook as "responsible and prudent" while outlining strategic investments and a landmark partnership with the U.S. government.

Thermo Fisher Scientific Launches Orbitrap Mass Spectrometers for Isotope Ratio Analysis

https://www.mpo-mag.com/breaking-news/thermo-fisher-scientific-launches-orbitrap-mass-spectrometers-for-isotope-ratio-analysis/
Thermo Fisher Scientific has launched its first Orbitrap mass spectrometers dedicated to isotope ratio analysis: the Orbitrap Isora MS and Orbitrap Isora Pro MS. These instruments, integrated with the Vanquish Duo UHPLC System and new Isotope Discoverer Software, create a workflow that makes molecular-level isotope ratio analysis more accessible to researchers. This innovation aims to accelerate discoveries in environmental science, geoscience, bioscience, and food authenticity by providing detailed insights into compound origins and molecular processes.

Missed Thermo Fisher Scientific's Run? What Holders Had To Believe

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/missed-thermo-fisher-scientifics-run-what-holders-had-to-bel
Thermo Fisher Scientific's stock has returned 24.8% over the past year despite mixed market signals. The article explores the contrasting bullish and bearish narratives that investors faced, highlighting that the recent run effectively prices in the company's ability to convert pharma, biotech, and bioproduction momentum into durable organic growth, a point that conflicts with some current fair value estimates. It also touches upon a related business that provides essential testing for health data chips and drives robotics in data centers, indicating further growth potential if life sciences computing demand continues.

BD Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results

https://www.tradingview.com/news/prnewswire:f7b03abac1b68:0-bd-reports-fourth-quarter-and-full-year-fiscal-2026-financial-results/
BD (Becton, Dickinson and Company) announced strong financial results for its fiscal 2026 fourth quarter and full year, ending September 30, 2026, with Q4 revenue of $5.3 billion and full-year revenue of $19.5 billion. The company reported significant increases in both GAAP and adjusted diluted EPS, along with substantial growth in cash from continuing operations and free cash flow. BD also issued its fiscal 2027 guidance and highlighted recent business achievements, including a major partnership with the U.S. Government for domestic manufacturing expansion and advancements in Connected Care and Interventional segments.

Agilent (A) Stock Looks Overvalued Following Its 66% Three Year Run

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-a/agilent-technologies/news/agilent-a-stock-looks-overvalued-following-its-66-three-year
Agilent Technologies (A) has experienced a significant 65.6% stock increase over the past three years, prompting questions about its current valuation. A Discounted Cash Flow (DCF) analysis suggests that the stock, trading at $177.17, may be overvalued as its intrinsic value based on future cash flows is estimated to be substantially lower. While recent acquisitions like Proscia, which add recurring revenue software, could influence investor confidence, the model still indicates the stock is above its fair value.
Advertisement

Revenue rose to $145.5M at Cytek Biosciences (CTKB), but its nine-month loss widened.

https://www.stocktitan.net/sec-filings/CTKB/10-q-cytek-biosciences-inc-quarterly-earnings-report-3d3fbb0140d1.html
Cytek Biosciences (CTKB) reported increased revenue for both the third quarter and the first nine months of 2026, reaching $53.2 million and $145.5 million, respectively. However, the company's net loss widened to $37.1 million for the nine-month period, up from $22.5 million in the prior year, primarily due to higher litigation expenses and bad debt reserves. The company is also involved in ongoing patent litigation with Beckman Coulter, Inc., where a jury awarded $56.11 million in past damages against Cytek, though the judgment is not final.

Waters CEO Udit Batra Announces Acquisition of MOBILion Systems to Expand Proteomics and AI-Driven Research Capabilities

https://indianewengland.com/waters-ceo-udit-batra-announces-acquisition-of-mobilion-systems-to-expand-proteomics-and-ai-driven-research-capabilities/
Waters Corporation has acquired MOBILion Systems Inc., a developer of high-resolution ion mobility separation technology, to expand its presence in the proteomics market and advance AI-driven biomedical research. This acquisition integrates MOBILion's SLIM technology with Waters' mass spectrometry platform, enhancing molecular separation capabilities for complex biological molecules. The move is expected to strengthen Waters' leadership in proteomics research and pave the way for future clinical and diagnostic applications, including AI-driven experimental design.

TD Cowen maintains Waters at Buy, raises price target to $530 from $515

https://www.tradingview.com/news/tradingview:179d832633f4d:0-td-cowen-maintains-waters-at-buy-raises-price-target-to-530-from-515/
TD Cowen has reiterated its "Buy" rating for Waters and increased its price target to $530 from $515, representing a 2.9% rise. This new price target suggests a 15.2% upside from the stock's closing price of $459.90 on November 3. Other analysts also issued positive ratings for Waters around the same time, with price targets ranging from $500 to $530.

Top Players Merck KGaA, Danaher, and Sartorius in the Next-Generation Biomanufacturing Market as It Reaches USD 44.37 Billion by 2035

https://www.openpr.com/news/4680954/top-players-merck-kgaa-danaher-and-sartorius-in
The global next-generation biomanufacturing market is projected to grow from USD 22.98 billion in 2025 to USD 44.37 billion by 2035, driven by advancements in bioprocessing technologies and rising demand for biologics. Upstream biomanufacturing and monoclonal antibodies are expected to be the leading segments by workflow and application, respectively. Key players include Thermo Fisher Scientific, Merck KGaA, Danaher Corporation, and Sartorius AG, with the United States and South Korea showing the fastest projected growth.

Waters buys MOBILion to push into the $2 billion LC-MS proteomics market

https://www.marketscale.com/industries/sciences/waters-buys-mobilion-to-push-into-the-2-billion-lc-ms-proteomics-market
Waters Corporation has acquired MOBILion Systems and its ion mobility technology to enter the $2 billion LC-MS proteomics market. While Waters' core business saw 9% growth driven by routine drug and environmental testing, the MOBILion acquisition represents a strategic research bet on proteomics, aiming to enhance throughput for large cohort studies through SLIM technology. The company projects increased organic growth and anticipates AI-related demand to potentially accelerate MOBILion's contribution to revenue.
Advertisement

Why Did Illumina Stock Jump?

https://www.trefis.com/stock/ilmn/articles/622671/why-did-illumina-stock-jump/2026-11-04
Illumina's stock jumped over 5% after the company announced its selection to provide whole-genome sequencing services for a national study in Singapore, which aims to sequence approximately 450,000 people. This move aligns with Illumina's focus on clinical sales growth, which management sees as a key driver for the future. Despite the jump, the stock remains down from its 52-week high but has delivered strong returns over the past year.

Danaher (DHR), Why Is It Drawing Fresh Attention Today?

https://sg.finance.yahoo.com/news/danaher-dhr-why-drawing-fresh-101407461.html
Danaher (DHR) is gaining attention due to U.S. regulatory clearance of its Access MeMed BV assay, a rapid test for distinguishing bacterial from viral infections. This approval follows strong third-quarter results and positive share price momentum, with the stock showing significant returns over 30 and 90 days. While one narrative suggests Danaher is undervalued with a fair value of $259.90, another perspective based on P/E multiples indicates the shares are trading at a premium compared to sector averages.

Waters Growth Prospects Accelerating on Artificial Intelligence and Reshoring Initiatives

https://www.morningstar.com/company-reports/1507522-waters-growth-prospects-accelerating-on-artificial-intelligence-and-reshoring-initiatives
Waters Corporation's growth is expected to accelerate due to increasing demand in life sciences, driven by artificial intelligence and reshoring initiatives. The company specializes in liquid chromatography and mass spectrometry products used by biopharmaceutical firms for drug analysis, as well as thermal analysis tools for material property examination. This positive outlook is reflected in strong profit boosts and updated 2026 guidance.

Agilent Technologies, Inc. (A) Stock forecasts

https://au.finance.yahoo.com/research/reports/ARGUS_3730_QuantitativeReport_1792540800000
Agilent Technologies, Inc. (A) received a "Raising target price to $190.00" rating from Argus on October 21, 2026. The company, originally spun out of Hewlett-Packard, is described as a leading life science and diagnostic firm with a current price of $175.46. The report suggests an upgrade for premium screener tools and exclusive reports.

ResMed Inc. (RMD) Stock forecasts

https://uk.finance.yahoo.com/research/reports/ARGUS_4219_QuantitativeReport_1791331200000
Argus lowered its target price for ResMed Inc. (RMD) to $243.00, while the current price stands at $227.08. ResMed is a leading global provider of respiratory care devices, specializing in products for sleep apnea treatment. The report also highlights other related analyst reports for various companies.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement